Table 1.

Effect of E/P and T/E/P treatment on the absolute count of peripheral lymphocytes over time

Cell population	Treatment	Slope (cells/µL per week)*	P value
CD19+ B cells	E/P	–3.20	<0.001
	T/E/P	–1.05	0.118
	Treatment–weeks interaction†	2.15	0.020
Total (CD3+) T cells	E/P	1.11	0.813
	T/E/P	16.08	0.002
	Treatment–weeks interaction†	14.97	0.032
CD8+ T cells	E/P	1.16	0.431
	T/E/P	6.99	<0.001
	Treatment–weeks interaction†	5.83	0.007
CD4+ T cells	E/P	0.99	0.727
	T/E/P	9.49	0.003
	Treatment–weeks interaction†	8.49	0.045

*Slope reflects the trend of absolute cell count over time as determined using a linear mixed-effects model.

†The treatment–weeks interaction between the slopes of the treatment groups (T/E/P vs E/P) was determined to evaluate the treatment effect of trilaciclib.

E/P, etoposide and carboplatin; T/E/P, trilaciclib prior to etoposide and carboplatin.